Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial
Titel:
Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial
Auteur:
Mirza, Mansoor Raza Åvall Lundqvist, Elisabeth Birrer, Michael J dePont Christensen, Rene Nyvang, Gitte-Bettina Malander, Susanne Anttila, Maarit Werner, Theresa L Lund, Bente Lindahl, Gabriel Hietanen, Sakari Peen, Ulla Dimoula, Maria Roed, Henrik Ør Knudsen, Anja Staff, Synnöve Krog Vistisen, Anders Bjørge, Line Mäenpää, Johanna U